Waiver Solution in Public Health and Pharmaceutical Domain under TRIPS Agreement
IR@NISCAIR: CSIR-NISCAIR, New Delhi - ONLINE PERIODICALS REPOSITORY (NOPR)
View Archive Info| Field | Value | |
| Creator |
Thapa, Rojina
|
|
| Date |
2011-11-11T11:21:46Z
2011-11-11T11:21:46Z 2011-11 |
|
| Identifier |
0975-1076 (Online); 0971-7544 (Print)
http://hdl.handle.net/123456789/13057 |
|
| Description |
470-476
WTO adopted the waiver solution in compulsory licensing, beginning from the Doha Declaration to the amendment of TRIPS Agreement, to facilitate access to medicine to the countries lacking manufacturing capacity. This article examines challenges faced by countries while issuing compulsory licensing; waiver decision with regard to Article 31(f) and 31 (h) of TRIPS Agreement. The article further analyses the causes as to why the waiver solution has not been as effective as it was hoped and envisages an increase in its importance in the coming days. |
|
| Language |
en_US
|
|
| Publisher |
NISCAIR-CSIR, India
|
|
| Rights |
<img src='http://nopr.niscair.res.in/image/cc-license-sml.png'> <a href='http://creativecommons.org/licenses/by-nc-nd/2.5/in' target='_blank'>CC Attribution-Noncommercial-No Derivative Works 2.5 India</a>
|
|
| Source |
JIPR Vol.16(6) [November 2011]
|
|
| Subject |
Compulsory licensing
TRIPS Agreement Doha Declaration Article 31 |
|
| Title |
Waiver Solution in Public Health and Pharmaceutical Domain under TRIPS Agreement
|
|
| Type |
Article
|
|